HK1129688A1 - Compositions and methods for the delivery of oxygen - Google Patents

Compositions and methods for the delivery of oxygen

Info

Publication number
HK1129688A1
HK1129688A1 HK09108182.2A HK09108182A HK1129688A1 HK 1129688 A1 HK1129688 A1 HK 1129688A1 HK 09108182 A HK09108182 A HK 09108182A HK 1129688 A1 HK1129688 A1 HK 1129688A1
Authority
HK
Hong Kong
Prior art keywords
delivery
methods
nox proteins
nox
type
Prior art date
Application number
HK09108182.2A
Other languages
English (en)
Inventor
Stephen P L Cary
Elizabeth M Boon
Emily Weinert
Jonathan A Winger
Michael A Marletta
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1129688A1 publication Critical patent/HK1129688A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/102499—Blood gas standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK09108182.2A 2006-05-22 2009-09-07 Compositions and methods for the delivery of oxygen HK1129688A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150506P 2006-05-22 2006-05-22
PCT/US2007/012184 WO2007139791A2 (en) 2006-05-22 2007-05-21 Compositions and methods for the delivery of oxygen

Publications (1)

Publication Number Publication Date
HK1129688A1 true HK1129688A1 (en) 2009-12-04

Family

ID=38779160

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09108182.2A HK1129688A1 (en) 2006-05-22 2009-09-07 Compositions and methods for the delivery of oxygen

Country Status (13)

Country Link
US (7) US8404631B2 (da)
EP (7) EP2463294B1 (da)
JP (5) JP5698906B2 (da)
CN (5) CN101495506B (da)
AU (2) AU2007268028B2 (da)
BR (2) BRPI0711901A2 (da)
CA (2) CA2653101C (da)
DK (4) DK2463297T3 (da)
ES (4) ES2399662T3 (da)
HK (1) HK1129688A1 (da)
IN (2) IN2013MN00600A (da)
NZ (4) NZ594456A (da)
WO (2) WO2007139767A2 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2013MN00600A (da) 2006-05-22 2015-06-12 Univ California
US20110243849A1 (en) * 2010-04-02 2011-10-06 Marletta Michael A Heme-binding photoactive polypeptides and methods of use thereof
EP3922643A1 (en) * 2013-01-07 2021-12-15 Omniox, Inc. Polymeric forms of h-nox proteins
MA41788A (fr) * 2015-03-17 2021-03-31 Omniox Inc Modulation de l'immunité tumorale par proteines médiatrices de la délivrance d'o2
CN109069582A (zh) 2016-02-16 2018-12-21 欧姆尼奥克斯公司 与中风有关的缺氧的调节
JP6467073B2 (ja) * 2018-01-04 2019-02-06 オムニオクス， インコーポレイテッド Ｈ−ｎｏｘタンパク質の重合体形態
EP3836911A1 (en) 2018-08-15 2021-06-23 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
CN114555123B (zh) 2019-10-18 2024-04-02 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
AU2020374947A1 (en) 2019-10-31 2022-03-31 Forty Seven, Inc. Anti-CD47 and anti-CD20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
US11845723B2 (en) 2019-12-24 2023-12-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
MX2022013619A (es) 2020-05-01 2022-11-16 Gilead Sciences Inc Compuestos de 2,4-dioxopirimidina que inhiben cd73.
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN118139858A (zh) 2021-10-28 2024-06-04 吉利德科学公司 吡地嗪-3(2h)-酮衍生物
KR20240097895A (ko) 2021-10-29 2024-06-27 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
CA3239528A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
AU2023233730A1 (en) 2022-03-17 2024-09-26 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6022849A (en) 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US5731454A (en) * 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
AU6766994A (en) * 1994-04-01 1995-10-23 Unisyn Technologies, Inc. Culture media additives for hollow fiber bioreactors
DE69831248T2 (de) 1997-02-28 2006-04-13 The Regents Of The University Of California, Oakland Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
AU750295B2 (en) 1997-05-02 2002-07-11 Baxter Biotech Technology S.A.R.L. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
US6773613B1 (en) * 1998-10-15 2004-08-10 Sangart, Inc. Method for production of stroma-free hemoglobin
AU781444B2 (en) * 1999-12-22 2005-05-26 Scripps Research Institute, The Angiogenesis and vascular permeability modulators and inhibitors
CA2410953A1 (en) * 2000-06-29 2002-01-10 Incyte Genomics, Inc. Adenylyl and guanylyl cyclases
US20030096240A1 (en) * 2000-09-19 2003-05-22 Ferid Murad Genomic organization of mouse and human sGC
US6780849B2 (en) * 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
CN1660100A (zh) * 2002-12-09 2005-08-31 上海倍艺医药科技有限公司 一种治疗糖尿病及其并发症的药物
IN2013MN00600A (da) * 2006-05-22 2015-06-12 Univ California

Also Published As

Publication number Publication date
EP2032156A2 (en) 2009-03-11
CN101495506A (zh) 2009-07-29
EP2463294B1 (en) 2016-10-19
ES2399662T3 (es) 2013-04-02
CN101495134A (zh) 2009-07-29
JP2009538134A (ja) 2009-11-05
US20150266931A1 (en) 2015-09-24
EP2040740A4 (en) 2009-10-21
CA2653101C (en) 2016-12-13
AU2007268028B2 (en) 2013-03-14
ES2525226T3 (es) 2014-12-19
NZ594456A (en) 2013-06-28
US8404631B2 (en) 2013-03-26
WO2007139767A3 (en) 2008-02-07
EP2040740A2 (en) 2009-04-01
CN108273040A (zh) 2018-07-13
US20130289252A1 (en) 2013-10-31
CA2653101A1 (en) 2007-12-06
EP2463297B1 (en) 2016-10-19
JP2017137337A (ja) 2017-08-10
CA2653080C (en) 2019-02-12
US10202428B2 (en) 2019-02-12
EP2040740B1 (en) 2014-09-03
JP6118772B2 (ja) 2017-04-19
DK2040740T3 (da) 2014-12-01
JP5698905B2 (ja) 2015-04-08
JP6458070B2 (ja) 2019-01-23
JP2009538133A (ja) 2009-11-05
CN106075388A (zh) 2016-11-09
WO2007139791A3 (en) 2008-05-02
DK2463294T3 (da) 2017-01-16
BRPI0711767B1 (pt) 2018-05-15
DK2463297T3 (da) 2017-01-09
JP5698906B2 (ja) 2015-04-08
EP2474554A2 (en) 2012-07-11
EP2463296A1 (en) 2012-06-13
ES2610653T3 (es) 2017-04-28
WO2007139767A2 (en) 2007-12-06
IN2013MN00601A (da) 2015-06-12
US20150376250A1 (en) 2015-12-31
US9493527B2 (en) 2016-11-15
ES2611157T3 (es) 2017-05-05
JP2015007108A (ja) 2015-01-15
US8404632B2 (en) 2013-03-26
CN101495506B (zh) 2016-08-10
BRPI0711901A2 (pt) 2012-03-06
AU2007268052A1 (en) 2007-12-06
US9493526B2 (en) 2016-11-15
US20100285104A1 (en) 2010-11-11
IN2013MN00600A (da) 2015-06-12
EP2463295A1 (en) 2012-06-13
NZ594457A (en) 2013-06-28
AU2007268028A1 (en) 2007-12-06
NZ573004A (en) 2012-06-29
EP2463294A1 (en) 2012-06-13
EP2463297A1 (en) 2012-06-13
CN104689300A (zh) 2015-06-10
EP2474554A3 (en) 2012-10-03
BRPI0711767A2 (pt) 2012-01-10
US20100266673A1 (en) 2010-10-21
WO2007139791A2 (en) 2007-12-06
NZ573003A (en) 2012-06-29
CN104689300B (zh) 2018-06-05
US20170267732A1 (en) 2017-09-21
CN106075388B (zh) 2021-06-29
CN101495134B (zh) 2016-08-03
US20130288970A1 (en) 2013-10-31
AU2007268052B2 (en) 2013-07-04
EP2032156A4 (en) 2009-11-11
CA2653080A1 (en) 2007-12-06
EP2032156B1 (en) 2012-11-21
JP6118296B2 (ja) 2017-04-19
DK2032156T3 (da) 2013-02-18
BRPI0711767B8 (pt) 2021-05-25
JP2014224156A (ja) 2014-12-04

Similar Documents

Publication Publication Date Title
HK1129688A1 (en) Compositions and methods for the delivery of oxygen
MX2009005460A (es) (s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano.
CY1118222T1 (el) Συνθεσεις λυασης φαινυλαλανινης αμμωνιας προκαρυωτικων και μεθοδοι αγωγης καρκινου χρησιμοποιωντας συνθεσεις εξ' αυτης
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
TN2010000128A1 (en) Antibodies specific for the protofibril form of beta-amyloid protein
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2172246A3 (en) Methods for Alzheimer's disease treatment and cognitive enhancement
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
MY161991A (en) Proteasome inhibitors
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
IN2015DN02553A (da)
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
MY162174A (en) Azetidines mek inhibitors for the treatment of proliferative diseases
UA95235C2 (en) Glucagon-like-peptide-2 (glp-2) analogues
DE60330181D1 (de) Actriib-fusionspolypeptide und verwendungen dafür
PL1789398T3 (pl) Pochodne 2-amino-chinazoliny użyteczne jako inhibitory ß-sekretazy (BACE)
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
WO2006081435A3 (en) Method of providing readily available cellular material derived from cord blood, and a composition thereof
EA200500782A1 (ru) Лечение геморрагического шока
TW200736227A (en) New compounds III
MY150604A (en) 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities
WO2008113013A3 (en) C-met mutations and uses thereof
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole